New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
09:10 EDTAGIO, AEO, VOCS, PFE, MAT, MNK, WWE, MNKD, P, QCOROn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
News For QCOR;MNK;VOCS;P;MAT;AEO;MNKD;PFE;AGIO;WWE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
February 1, 2016
16:06 EDTMATMattel reports Q4 adjusted EPS 67c, consensus 61c
Reports Q4 revenue $1.99B, consensus $1.91B.
16:01 EDTPFEOptions Update; February 1, 2016
Subscribe for More Information
14:32 EDTPFENotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
14:32 EDTMATNotable companies reporting after market close
Subscribe for More Information
13:25 EDTPFEEarnings Watch: Pfizer shares down approximately 12% since last earnings report
Pfizer (PFE) is scheduled to report fourth quarter earnings before the market open on Tuesday, February 2, with a conference call scheduled for 10:00 am ET. Pfizer, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. EXPECTATIONS: Analysts are looking for earnings per share of 52c on revenue of $13.57B, according to First Call. The consensus range for EPS is 49c-54c on revenue of $13.08B-$13.99B. LAST QUARTER: After completing its Hospira acquisition in early September, Pfizer reported third quarter EPS of 60c, which beat consensus estimates of 51c, on revenue of $12.1B, which was also higher than consensus estimates of $11.56B. In Q3 Operational revenue growth in in developed markets was driven primarily by the performance of several key products, including Prevnar 13 in adults, Ibrance and Eliquis -- all products that are early in their life cycles as well as from Lyrica primarily in the U.S., and the inclusion of one month of legacy Hospira U.S. operations. In emerging markets, revenues increased 5% operationally, reflecting continued strong operational growth, primarily from the Innovative Products business. Operational revenue growth was partially offset primarily by the loss of exclusivity and associated generic competition for Celebrex in the U.S., Zyvox in the U.S. and Lyrica in certain developed Europe markets. With its Q3 earnings announcement the company raised its fiscal year 2015 earnings per share view to $2.16-$2.20 from $2.04-$2.10 against a raised revenue view of $47.5B-$48.5B from $46.5B-$47.5B. Commenting on the improved yearly view, the company CFO said "We raised our 2015 financial guidance for reported revenues and adjusted diluted EPS to reflect the strong performance to date of Pfizer-standalone, excluding legacy Hospira operations coupled with an improved business outlook for Pfizer-standalone for the remainder of the year.PFIZER-ALLERGAN DEAL. On November 23, Pfizer and Allergan (AGN) announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan. Pfizer at the time said it anticipates the Allergan transaction will deliver more than $2B in operational synergies over the first three years after closing. Pfizer anticipates that the combined company will have a pro forma Adjusted Effective Tax Rate of approximately 17%-18% by the first full year after the closing of the transaction. The transaction is expected to be neutral to Pfizer's Adjusted Diluted EPS in 2017, modestly accretive beginning in calendar year 2018, more than 10% accretive in 2019 with high-teens percentage accretion in 2020. STREET RESEARCH: On December 1, Barclays analyst Geoff Meacham kept an Equal Weight rating on Pfizer after assuming coverage of the name. The analyst maintained a $34 price target for shares.On November 25, SunTrust upgraded Pfizer to Neutral and increased its price target to $37 from $34 on shares. Analyst John Boris said the Allergan deal makes strategic sense, providing much needed growth from earlier life cycle assets with limited therapeutic overlap. PRICE ACTION: Shares of Pfizer are lower by approximately 12% since its last earnings report on October 27. Pfizer shares are trading over 1% lower to $29.97 in afternoon trading ahead of Tuesday morning's earnings.
12:27 EDTMATOptions with increasing put volume
Subscribe for More Information
10:49 EDTPFEPfizer technical comments before earnings
On the downside, an important support level to watch is at the $28 area. This level has been an important support since early 2013. If the news is a negative surprise, the $28 zone is likely to be tested from current levels. A breakdown below $28 would resolve the range bearishly. Next downside objectives may be at the following support levels: $27.30, $26.42. If the news is a bullish surprise, resistance levels to watch as potential upside objectives would be at $30.95, $31.78, and $32.91. A move above $32.50 would end the current longer-term downtrend.
08:51 EDTMNKThe Medicines Co. completes divestiture of hemostasis portfolio to Mallinckrodt
Subscribe for More Information
08:09 EDTPFEOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
06:58 EDTPFEPortola Pharma licensed right to andexanet alfa to Bristol-Myers and Pfizer
Subscribe for More Information
06:57 EDTPFEBristol-Myers and Pfizer sign collaboration with Portola Pharmaceuticals
Subscribe for More Information
January 29, 2016
17:45 EDTMATMattel acquires substantially all the assets of Fuhu
Subscribe for More Information
14:44 EDTPFEPfizer volatility elevated into Q4 and outlook
Subscribe for More Information
08:22 EDTMATMattel volatility elevated into Q4 and outlook
Mattel February call option implied volatility is at 45, March is at 34; compared to its 52-week range of 22 to 49, suggesting large near term price movement into the expected release of Q4 results on February 1.
05:39 EDTPFEPfizer: LIS awards infliximab biosimilar tender to Inflectra, Reuters reports
Pfizer says that the Norwegian Drug Procurement Cooperation has awarded its product Inflectra an infliximab biosimilar tender, Reuters reports. Reference Link
January 28, 2016
09:02 EDTPPandora launches Browse
Pandora launched Browse, a new way to help users discover even more music. "Finding new music should be a simple and enjoyable experience," said Chris Phillips, chief product officer of Pandora. "Our musicologists have scored millions of songs to find the perfect music just for you. The new Browse feature makes it easy to find the music you love whether you know what you want, or need a little help discovering music you didn't know existed." The service includes fresh station recommendations, music metrics, and the ability see what's spinning on a station before adding it to station list.
08:07 EDTWWE2K, WWE announce multi-year extension for WWE video game properties
2K (TTWO) and WWE (WWE) announced that the companies have extended their partnership with a new multi-year exclusive agreement granting 2K the worldwide rights to develop and publish WWE video game properties across all major platforms and distribution channels. WW 2K, the simulation-based flagship series developed by 2K's Visual Concepts studio and Yuke's, will continue an 18-year tradition established by past WWE titles, including the recently released WWE 2K16. In addition, 2K will continue to invest in WWE SuperCard, the breakout hit card-battling game developed by its Cat Daddy Games studio, which has been downloaded more than nine million times since its initial release. Financial terms of the new agreement were not disclosed.
05:43 EDTMNKDStocks with implied volatility movement; BTU MNKD
Subscribe for More Information
January 27, 2016
10:18 EDTMATMattel and Disney Consumer Products announce renewed agreement
Subscribe for More Information
09:46 EDTMNKDMannKind to host business news update conference call
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use